FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
April 19, 2018

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Moon Hee V. Choi, PharmD
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

G. Caleb Alexander, MD, MS
(Chairperson)
Associate Professor of Epidemiology and Medicine
Johns Hopkins Bloomberg School of Public Health
Center for Drug Safety and Effectiveness
Baltimore, Maryland

Mark W. Green, MD, FAAN
Professor of Neurology, Anesthesiology, and Rehabilitation Medicine
Director of Headache and Pain Medicine
Vice Chair of Neurology for Professional Development and Alumni Relations
Icahn School of Medicine at Mt Sinai
New York, New York

David S. Knopman, MD
Professor of Neurology
Mayo Clinic
Rochester, Minnesota

Richard J. Kryscio, PhD
Professor, Statistics and Biostatistics
University of Kentucky
Sanders-Brown Center on Aging
Lexington, Kentucky

Chiadi U. Onyike, MD, MHS
Associate Professor of Psychiatry and Behavioral Sciences
Division of Geriatric Psychiatry and Neuropsychiatry
Department of Psychiatry and Behavioral Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel S. Perlmutter, MD
Elliot Stein Family Professor of Neurology
Professor of Radiology, Neuroscience, Physical Therapy & Occupational Therapy
Washington University School of Medicine
St. Louis, Missouri

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Mark Forrest Gordon, MD
Senior Director
Clinical Development, Neurology and Psychiatry
Teva Pharmaceuticals
Malvern, Pennsylvania
TEMPORARY MEMBERS (Voting)

Jane B. Acri, PhD
Chief, Medication Discovery & Toxicology Branch
Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse
National Institutes of Health (NIH)
Bethesda, Maryland

Danielle Boyce, MPH
(Patient Representative)
Senior Research Data Analyst
Johns Hopkins University
Baltimore, Maryland

José E. Cavazos, MD, PhD
Professor of Neurology, Neuroscience, and Physiology
Assistant Dean & Director, MD/PhD Program
University of Texas Health San Antonio
San Antonio, Texas

Harriet de Wit, PhD
Professor
Department of Psychiatry and Behavioral Neuroscience
University of Chicago
Chicago, Illinois

Richard P. Hoffman, PharmD
(Acting Consumer Representative)
Pharmacist/Medical Writer
Hernando, Florida

John Mendelson, MD
Senior Research Scientist, Friends Research Institute
Founder and Chief Medical Officer, Ria Health
San Francisco, California

Eluen Ann Yeh, MA, MD, FRCPC, Dip ABPN
Associate Professor, Faculty of Medicine
University of Toronto
Director, Pediatric MS and Demyelinating Disorders Program
Associate Scientist, Neurosciences and Mental Health, SickKids Research Institute
Staff Physician, Division of Neurology
The Hospital for Sick Children,
Toronto, Ontario, Canada

FDA PARTICIPANTS (Non-Voting)

Ellis Unger, MD
Director, Office of Drug Evaluation I (ODE-I)
Office of New Drugs (OND), CDER, FDA

Robert Temple, MD
Deputy Director
ODE-I, OND, CDER, FDA

Billy Dunn, MD
Director, Division of Neurology Products (DNP)
ODE-I, OND, CDER, FDA

Eric Bastings, MD
Deputy Director
DNP, ODE-I, OND, CDER, FDA

Teresa Buracchio, MD
Clinical Team Leader
DNP, ODE-I, OND, CDER, FDA

Dominic Chiapperino, PhD
Acting Director, Controlled Substance Staff
Office of the Center Director, CDER, FDA